Francesca Bruce
Senior Writer
Latest From Francesca Bruce
German HTA: Clinical Cancer Registries Could Hold Key To Better Comparative Data For Benefit Assessments
Better data linkage and data entry systems could transform Germany’s clinical cancer registries into a reliable data source for health technology assessments.
European Health Data Space Talks Falter Over Opt-Out Issue
The pharmaceutical industry has warned co-legislators against any hasty compromises that could impact the competitiveness of EU research.
Germany’s Confidential Pricing Move Could Protect Companies From Potential Trumpian US Reference Pricing
Confidential pricing would give companies more flexibility to negotiate discounts and prevent withdrawals.
Pfizer Ponders Next Move After English HTA Rejects Oxbryta Again Despite Appeal
In spite of successfully appealing against previous negative guidance, Pfizer has again failed to secure a positive recommendation from England’s health technology appraisal institute for Oxbryta for hemolytic anemia caused by sickle cell disease, and has been asked to provide more evidence.
English & Scottish HTAs Diverge On Sanofi’s Dupixent For Rare Skin Condition
The Scottish health technology appraisal body, the SMC, has announced its recommendations on Sanofi’s Dupixent, Ipsen’s Cabometyx, Sobi’s Zynlonta and Novartis’ Cosentyx.
BMS Secures Better HTA Result In Germany With Additional Data for Camzyos
A revised benefit rating for BMS’ cardiomyopathy drug Camzyos will be good news for the product’s pricing in Germany.